HK Stock Market Move | HENLIUS (02696) rises over 3% again, anti-PD-1 monoclonal antibody H "Hanshuang" makes its debut on "News Broadcast".

HENLIUS (02696) rose again by more than 3%, with a cumulative increase of over 27% this month. As of the time of writing, it rose by 3.73%, priced at HKD 70.95, with a trading volume of HKD 20.4885 million. In terms of news, on the evening of August 8, CCTV-1's "News Broadcast" focused on the innovative breakthroughs in China's pharmaceutical industry in the first half of the year, featuring HENLIUS's independently developed anti-PD-1 monoclonal antibody H drug Hanshuoz (sruvolumab, European trade name: Hetronifly) as a representative of domestic innovative drugs. The report mentioned: "This innovative drug for gastric cancer, launched this year as the world's first 'non-chemotherapy' treatment, had already secured overseas revenues through authorization before its market release and has been exported to multiple countries and regions worldwide." It is noteworthy that the 2026 World Lung Cancer Conference (WCLC) will be held from September 12 to 15 in Seoul, South Korea. HENLIUS will announce multiple recent research findings on its innovative products at this conference, covering Phase I research data for PD-L1ADCHLX43 in the area of thymic squamous cell carcinoma (TSCC), as well as seven research data points on the anti-PD-1 monoclonal antibody H drug Hanshuoz in extensive stage small cell lung cancer, limited stage small cell lung cancer, and large cell neuroendocrine carcinoma.